Novo Holdings Invests £50m in Oxford Nanopore Technologies

Novo Holdings Invests $72 Million in LanzaTech

August 6, 2019

Biotechnology

Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.

Novo Holdings Acquires BBI Group

June 15, 2021

Medical Devices

Novo Holdings A/S has agreed to acquire BBI Group from Exponent for an enterprise value of over GBP 400 million, becoming the company's majority shareholder. BBI, a Crumlin, South Wales–headquartered supplier of diagnostics reagents, lateral flow development and diagnostic manufacturing services with more than 400 employees, will benefit from Novo Holdings' life-sciences expertise to pursue organic and inorganic growth.

Novo Holdings Leads $50M Growth Investment in MedGenome

August 30, 2022

Biotechnology

Novo Holdings led a $50 million minority investment in MedGenome alongside existing investors LeapFrog Investments and Sofina. The capital will support MedGenome’s expansion beyond South Asia into Africa and the Middle East and broaden access to its genomic testing, bioinformatics and research services.

Novo Holdings Invests $40M in Evosep

January 9, 2023

Biotechnology

Novo Holdings has invested $40 million in Evosep to accelerate the commercialization and clinical application of Evosep’s standardized proteomics liquid chromatography platform. The funds will support product development and global expansion — particularly into the U.S. — and Novo Holdings’ principal, Stephen Van Helden, will join Evosep’s board.

Novo Holdings Acquires Double-Digit Stake in bioMASON

December 17, 2019

Manufacturing

Novo Holdings A/S made a multimillion-dollar, double-digit equity investment in US-based bioMASON to help commercialize its bacteria-grown biocement masonry products. As part of the deal Anders Spohr of Novo Holdings will join bioMASON's board as the company scales its sustainable concrete alternative for construction and infrastructure markets.

Novo Holdings Acquires Majority Stake in Single Use Support

May 15, 2024

Biotechnology

Novo Holdings A/S agreed to acquire an approximately 60% controlling stake in Single Use Support, a Kufstein, Austria-based life science tools company specializing in fluid management, single-use consumables and cold-chain solutions for bioprocessing. The two founders will each retain 10% and Danaher will retain 20%; the investment is intended to support Single Use Support's next phase of global growth, particularly expansion into the US and Asia, and is subject to regulatory approvals.